1 citations
,
April 2023 in “Canadian journal of ophthalmology” Using a diode laser for hair removal without eye protection can cause serious eye injuries.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
54 citations
,
September 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Vitamin A affects hair loss and immune response in alopecia areata.
July 2025 in “Dermatology Practical & Conceptual” Topical eyedrops may cause eyelash whitening and skin lightening around the eyes.
64 citations
,
March 2008 in “Neuropsychopharmacology” 1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
January 1990 in “Irish Journal of Medical Science (1971 -)” Retinoids are important for treating skin conditions but should be used with caution due to serious side effects and risks during pregnancy.
March 2026 in “Microchemical Journal”
April 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Retinoic acid helps activate hair growth in people with common hair loss by working on a specific cell growth pathway.
July 2012 in “Reactions Weekly” Minoxidil use was linked to a rare eye condition that improved after stopping the treatment.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
2 citations
,
August 2023 in “Molecules” SH-340 may improve skin barrier and help treat atopic dermatitis.
1′S-1′-Acetoxychavicol acetate may help treat hair loss by reducing oxidative stress.
October 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” High retinol intake may worsen hair loss in alopecia areata.
12 citations
,
January 2021 in “Dermatology Research and Practice” The 1927 nm Thulium laser effectively and safely treats postinflammatory hyperpigmentation in darker skin tones.
July 1989 in “British Journal of Dermatology” Long-term use of canthaxanthin may cause reversible changes in the eye, including crystal deposits and altered vision responses.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Different types of human skin cells respond uniquely to various colors and doses of light, which could lead to specialized light treatments for skin conditions.
October 1940 in “Clinical and Experimental Optometry” Vitamin A deficiency can cause eye problems and other health issues.
27 citations
,
October 1945 in “Endocrinology” Synthetic hormone treatment reduces melanin and hair growth in rats.
3 citations
,
November 2023 in “Journal of Investigative Dermatology” Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
August 2021 in “Journal of advances in medicine and medical research” Excimer light therapy is more effective than low level laser therapy for treating alopecia areata.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
6 citations
,
February 2019 in “JAAD case reports” Acitretin helped improve hand mobility and skin condition in a patient.
29 citations
,
October 2009 in “Pharmacology Biochemistry and Behavior”
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.